share_log

藥明生物:翌日披露報表

WUXI BIO: Next Day Disclosure Return

香港交易所 ·  Apr 3 20:37
Summary by Futu AI
藥明生物技術有限公司(药明生物)於2024年4月3日完成了一系列股份購回活動,並於香港聯合交易所有限公司(香港聯交所)披露相關變動。根據披露報表,該公司在2023年12月7日至2024年4月3日期間,透過香港聯交所進行了多次股份購回,合計購回股份數目達87,177,000股,佔已發行股份的2.05199%。其中,2024年4月3日當天購回股份565,000股,每股價格介於HKD 14.04至HKD 14.1之間,總付出金額為HKD 7,943,880。此外,同日亦有股份期權行使,新增發行股份359,100股,每股發行價為HKD 2.18,較當日收市價HKD 14.2有84.65%的折讓。藥明生物確認已收取全部款項,並已履行所有上市規則要求的先決條件。截至2024年4月3日,藥明生物的結存已發行股份為4,258,970,569股。
藥明生物技術有限公司(药明生物)於2024年4月3日完成了一系列股份購回活動,並於香港聯合交易所有限公司(香港聯交所)披露相關變動。根據披露報表,該公司在2023年12月7日至2024年4月3日期間,透過香港聯交所進行了多次股份購回,合計購回股份數目達87,177,000股,佔已發行股份的2.05199%。其中,2024年4月3日當天購回股份565,000股,每股價格介於HKD 14.04至HKD 14.1之間,總付出金額為HKD 7,943,880。此外,同日亦有股份期權行使,新增發行股份359,100股,每股發行價為HKD 2.18,較當日收市價HKD 14.2有84.65%的折讓。藥明生物確認已收取全部款項,並已履行所有上市規則要求的先決條件。截至2024年4月3日,藥明生物的結存已發行股份為4,258,970,569股。
Pharmaceutical Biotechnology Co., Ltd. (Pharmaceutical Biologics) completed a series of share repurchase activities on 3 April 2024 and disclosed the relevant changes to the Hong Kong Stock Exchange Limited (HKEX). According to the disclosure statement, the company conducted multiple share repurchases through the Hong Kong Stock Exchange between December 7, 2023 and April 3, 2024, totaling 87,177,000 shares, accounting for 2.05199 percent of the issued shares. Of these, 565,000 shares were repurchased on 3 April 2024 at a price of between HKD 14.04 and HKD 14.1 for a total payment of HKD 7,943,880. In addition, a share option was exercised on the same day, adding 359,100 shares to the issue at HKD 2.18 per share, representing a discount of 84.65% from the current closing price of HKD 14.2. Pharma confirms that all payments have been received and that all the prerequisites required by the Listing Rules have been met. As of April 3, 2024, the outstanding shares of Pharmaceutical Biologics were issued in the amount of 4,258,970,569 shares.
Pharmaceutical Biotechnology Co., Ltd. (Pharmaceutical Biologics) completed a series of share repurchase activities on 3 April 2024 and disclosed the relevant changes to the Hong Kong Stock Exchange Limited (HKEX). According to the disclosure statement, the company conducted multiple share repurchases through the Hong Kong Stock Exchange between December 7, 2023 and April 3, 2024, totaling 87,177,000 shares, accounting for 2.05199 percent of the issued shares. Of these, 565,000 shares were repurchased on 3 April 2024 at a price of between HKD 14.04 and HKD 14.1 for a total payment of HKD 7,943,880. In addition, a share option was exercised on the same day, adding 359,100 shares to the issue at HKD 2.18 per share, representing a discount of 84.65% from the current closing price of HKD 14.2. Pharma confirms that all payments have been received and that all the prerequisites required by the Listing Rules have been met. As of April 3, 2024, the outstanding shares of Pharmaceutical Biologics were issued in the amount of 4,258,970,569 shares.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.